BioAdvance News

FDA Accepts Filing of New Drug Application (NDA) for Yaupon’s Proprietary Gel Formulation of Mechlorethamine Hydrochloride

By WebmasterOctober 4, 2011November 1st, 2024No Comments

FDA Accepts Filing of New Drug Application (NDA) for Yaupon’s Proprietary Gel Formulation of Mechlorethamine Hydrochloride
Read more here

Previous PostBioAdvance’s ROI Tops $11 Million
Next PostNiiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339